Roivant Sciences Ltd.

Historical 13F Holders

Symbol
ROIV
CUSIP
G76279101
All holders as of
Q2 2026
Type
Equity
Class
SHS
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for G76279101 since 12/18/2024, newest first.

Filer % of Class Filed
Morgan Stanley 13G/A Amendment 3
5.7% 8/13/2026
Event 6/30/2026
Morgan Stanley 13G/A Amendment 2
6.9% 5/12/2026
Event 3/31/2026
Ramaswamy Vivek 13G/A Amendment 7 3.6% 5/6/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 2 0% 3/27/2026
Event 3/13/2026
FMR LLC 13G/A Amendment 3
10.3% 3/6/2026
Event 2/27/2026
SB Investment Advisers (UK) Ltd 13G/A Amendment 5
2.3% 2/17/2026
Event 12/31/2025
Ramaswamy Vivek 13G/A Amendment 6 6.8% 2/13/2026
Event 12/31/2025
Morgan Stanley 13G/A Amendment 1
8.0% 2/11/2026
Event 12/31/2025
FMR LLC 13G/A Amendment 2
9.5% 2/5/2026
Event 12/31/2025
SB Investment Advisers (UK) Ltd 13G/A Amendment 4
5.8% 11/14/2025
Event 9/30/2025
Viking Global Investors LP 13G/A Amendment 6
3.4% 11/14/2025
Event 9/30/2025
QVT Financial LP 13G/A Amendment 5 4.3% 8/14/2025
Event 6/30/2025
Viking Global Investors LP 13G/A Amendment 5
5.0% 8/14/2025
Event 6/30/2025
Morgan Stanley 13G
5.5% 8/7/2025
Event 6/30/2025
FMR LLC 13G/A Amendment 1
8.2% 8/6/2025
Event 6/30/2025
Ramaswamy Vivek 13G/A Amendment 5 11.6% 5/15/2025
Event 3/31/2025
Ramaswamy Vivek 13G/A Amendment 4 11.2% 5/15/2025
Event 12/31/2024
Viking Global Investors LP 13G/A Amendment 4
6.4% 5/15/2025
Event 3/31/2025
SB Investment Advisers (UK) Ltd 13G/A Amendment 3
8.5% 2/14/2025
Event 12/31/2024
QVT Financial LP 13G/A Amendment 4 9.2% 2/14/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 21 7.48 M $273 M
2026 Q2 526 584 M $20.5 B
2026 Q1 473 531 M $14.7 B
2025 Q4 428 509 M $11.0 B
2025 Q3 370 503 M $7.61 B
2025 Q2 362 516 M $5.82 B
2025 Q1 334 558 M $5.63 B
2024 Q4 339 563 M $6.65 B
2024 Q3 317 572 M $6.60 B
2024 Q2 314 576 M $6.09 B
2024 Q1 275 604 M $6.36 B
2023 Q4 249 564 M $6.34 B
2023 Q3 220 546 M $6.38 B
2023 Q2 187 498 M $5.02 B
2023 Q1 156 459 M $3.39 B
2022 Q4 118 415 M $3.32 B
2022 Q3 86 371 M $1.19 B
2022 Q2 78 360 M $1.47 B
2022 Q1 57 349 M $1.72 B
2021 Q4 45 339 M $3.42 B